PD-1 Antibody SHR-1210 Combined With Paclitaxel and Cisplatin Versus Placebo Combined With Paclitaxel and Cisplatin as First-line Therapy for Advanced Esophageal Cancer: a Randomized, Double-blinded, Controlled, Multi-center Phase III Trial
Phase of Trial: Phase III
Latest Information Update: 03 Apr 2019
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 28 Mar 2019 Status changed from not yet recruiting to recruiting.
- 09 Oct 2018 New trial record